Dataset Information

Ascites MV - Proteomic analysis of microvesicles derived from human colorectal cancer ascites

ABSTRACT: Microvesicles purified from ascites of three CRC-patients with the combination of 1D SDS-PAGE and nano-LC-MS/MS

INSTRUMENT(S): instrument model, LTQ

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ascites

DISEASE(S): Stage Iv Colorectal Cancer

SUBMITTER: Doyoung Choi

PROVIDER: PRD000354 | Pride | 2011-06-23

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	PRIDE_Exp_Complete_Ac_15824.pride.mgf.gz	Mgf
	PRIDE_Exp_Complete_Ac_15824.pride.mztab.gz	Mztab
	PRIDE_Exp_Complete_Ac_15824.xml.gz	Xml
	PRIDE_Exp_Complete_Ac_15825.pride.mgf.gz	Mgf
	PRIDE_Exp_Complete_Ac_15825.pride.mztab.gz	Mztab

Items per page:

1 - 5 of 9

Publications

Proteomic analysis of microvesicles derived from human colorectal cancer ascites.

Choi Dong-Sic DS Park Jung Ok JO Jang Su Chul SC Yoon Yae Jin YJ Jung Jin Woo JW Choi Do-Young DY Kim Jung-Wook JW Kang Ji Seon JS Park Jaesung J Hwang Daehee D Lee Kyung-Hee KH Park Sang-Hyun SH Kim Yoon-Keun YK Desiderio Dominic M DM Kim Kwang Pyo KP Gho Yong Song YS

Proteomics 20110601 13

The presence of malignant ascites in the peritoneal cavity is a poor prognostic indicator of low survival rate. Various cancer cells, including those of colorectal cancer (CRC), release microvesicles (exosomes) into surrounding tissues and peripheral circulation including malignant ascites. Although recent progress has revealed that microvesicles play multiple roles in tumor progression, the protein composition and the pathological function of malignant ascites-derived microvesicles are still un ...[more]

PMID: 21630462

Similar Datasets

Project description:Microvesicles (MV) are small membrane-bound particles comprised of exosomes and various sized extracellular vesicles. These are released by a number of cell types. Microvesicles have a variety of cellular functions from communication to mediating growth and differentiation. Microvesicles contain proteins and nucleic acids. Previously, we showed that plasma microvesicles contain microRNAs (miRNAs). Based on our previous report, the majority of peripheral blood microvesicles are derived from platelets while mononuclear phagocytes, including macrophages, are the second most abundant population. Here, we characterized macrophage-derived microvesicles and whether they influenced the differentiation of naM-CM-/ve monocytes. We also identified the miRNA content of the macrophage-derived microvesicles. We found that RNA molecules contained in the macrophage-derived microvesicles were transported to target cells, including monocytes, endothelial cells, epithelial cells and fibroblasts. Furthermore, we found that miR-223 was transported to target cells and was functionally active. Based on our observations, we hypothesize that microvesicles bind to and activate target cells. Furthermore, we find that microvesicles induce the differentiation of macrophages. Thus, defining key components of this response may identify novel targets to regulate host defense and inflammation. We used GeneChip microarrays to examine changes in gene expression induced by MV in primary monocyte-derived macrophages (MDM) and in THP1 cells, and compare this to cells treated with GM-CSF and PMA, respectively. All experiments were done in triplicates. Primary monocytes were collected from buffy coats (BC). The freshly isolated monocytes from three donors (Mono1-3) were either treated with GM-CSF or subjected to RNA isolation. Following treatment, MVs were isolated from the GM-CSF-treated macrophage cultures. RNA was isolated from the remaining cells for profiling (GM1-3). The isolated MVs were then used to treat new BC monocytes for 24 h (BC-GMCSF-MV24). A fraction of the new BC monocytes was subjected to RNA extraction for profiling (BC1-3). For THP1 cells, they were treated with either DMSO or PMA to produce MVs. The MVs were collected and the remaining cells lyzed for RNA extraction and profiling (DMSO1-3 and PMA1-3). The collected MVs from the DMSO or PMA-treated THP1 cells were incubated with new THP1 for 24 h and designated DMSO-MV24 or PMA-MV24. We had a total of 24 samples.